--- title: "mRNA Therapies" slug: "mrna-therapies" discipline: "Medicine / Biotechnology" description: "mRNA-based therapeutics and vaccines. From COVID-19 vaccines to cancer immunotherapy, personalized medicine, and next-generation mRNA delivery platforms." icon: "💉" url: "https://science-database.com/technology/mrna-therapies" api: "https://science-database.com/api/v1/technology/mrna-therapies" llms_txt: "https://science-database.com/technology/mrna-therapies/llms.txt" articles_indexed: 15 last_updated: "2026-09-08T05:19:42.363Z" search_terms: - "mRNA vaccine therapy" - "mRNA lipid nanoparticle delivery" - "mRNA cancer immunotherapy" source: "science-database.com" license: "metadata CC0, abstracts belong to respective publishers" --- # mRNA Therapies mRNA-based therapeutics and vaccines. From COVID-19 vaccines to cancer immunotherapy, personalized medicine, and next-generation mRNA delivery platforms. **Discipline:** Medicine / Biotechnology **Indexed Papers:** 15 **Last Updated:** 2026-09-08 ## Top Publications Ranked by citation impact across Semantic Scholar, OpenAlex & arXiv. ### mRNA vaccines — a new era in vaccinology - **Authors:** Norbert Pardi, Michael J. Hogan, Frederick Porter, Drew Weissman - **Journal:** Nature Reviews Drug Discovery - **Published:** 2018-01-12 - **DOI:** [10.1038/nrd.2017.243](https://doi.org/10.1038/nrd.2017.243) - **Citations:** 4,664 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://www.nature.com/articles/nrd.2017.243.pdf) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W2782708334/llms.txt) ### Lipid nanoparticles for mRNA delivery - **Authors:** Xucheng Hou, Tal Zaks, RĂłbert Langer, Yizhou Dong - **Journal:** Nature Reviews Materials - **Published:** 2021-08-10 - **DOI:** [10.1038/s41578-021-00358-0](https://doi.org/10.1038/s41578-021-00358-0) - **Citations:** 3,923 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://www.nature.com/articles/s41578-021-00358-0.pdf) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3188940990/llms.txt) ### mRNA vaccines for infectious diseases: principles, delivery and clinical translation - **Authors:** Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead - **Journal:** Nature Reviews Drug Discovery - **Published:** 2021-08-25 - **DOI:** [10.1038/s41573-021-00283-5](https://doi.org/10.1038/s41573-021-00283-5) - **Citations:** 1,552 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://www.nature.com/articles/s41573-021-00283-5.pdf) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3193427089/llms.txt) ### mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability - **Authors:** Linde Schoenmaker, Dominik Witzigmann, Jayesh A. Kulkarni, Rein Verbeke, Gideon Kersten, Wim Jiskoot, Daan J.A. Crommelin - **Journal:** International Journal of Pharmaceutics - **Published:** 2021-04-08 - **DOI:** [10.1016/j.ijpharm.2021.120586](https://doi.org/10.1016/j.ijpharm.2021.120586) - **Citations:** 1,544 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://www.sciencedirect.com/science/article/pii/S0378517321003914/pdf) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3148255637/llms.txt) > A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they have to be stored at (ultra)low temperatures. Understanding the root cause of the instability of these vaccines may help to rationally improve mRNA-LNP product stability and thereby ease the temperature conditions for storage. In this review we discuss proposed structures of mRNA-LNPs, factors that impact mRNA-L... ### mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants - **Authors:** Zijun Wang, Fabian Schmidt, Yiska Weisblum, Frauke Muecksch, Christopher O. Barnes, Shlomo Finkin, Dennis Schaefer-Babajew, Melissa Cipolla, Christian Gaebler, Jenna Ariel Lieberman, Thiago Y. Oliveira, Zhi Yang, Morgan E. Abernathy, Kathryn E. Huey‐Tubman, Arlene Hurley, Martina Turroja, Kamille A. West, Kristie Gordon, Katrina G. Millard, VĂ­ctor Ramos, Justin Da Silva, Jianliang Xu, Robert A. Colbert, Roshni Patel, Juan Dizon, Cecille Unson-O’Brien, Irina Shimeliovich, Anna Gazumyan, Marina Caskey, Pamela J. Björkman, Rafael Casellas, ThĂ©odora Hatziioannou, Paul D. Bieniasz, Michel C. Nussenzweig - **Journal:** Nature - **Published:** 2021-02-10 - **DOI:** [10.1038/s41586-021-03324-6](https://doi.org/10.1038/s41586-021-03324-6) - **Citations:** 1,517 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://www.nature.com/articles/s41586-021-03324-6.pdf) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3126729284/llms.txt) ### The role of lipid components in lipid nanoparticles for vaccines and gene therapy - **Authors:** Camilla Hald Albertsen, Jayesh A. Kulkarni, Dominik Witzigmann, Marianne Lind, Karsten Petersson, Jens B. Simonsen - **Journal:** Advanced Drug Delivery Reviews - **Published:** 2022-07-03 - **DOI:** [10.1016/j.addr.2022.114416](https://doi.org/10.1016/j.addr.2022.114416) - **Citations:** 1,163 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://www.ncbi.nlm.nih.gov/pmc/articles/9250827) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W4283803576/llms.txt) ### mRNA vaccine for cancer immunotherapy - **Authors:** Lei Miao, Yu Zhang, Leaf Huang - **Journal:** Molecular Cancer - **Published:** 2021-02-25 - **DOI:** [10.1186/s12943-021-01335-5](https://doi.org/10.1186/s12943-021-01335-5) - **Citations:** 935 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://molecular-cancer.biomedcentral.com/track/pdf/10.1186/s12943-021-01335-5) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3130729977/llms.txt) > mRNA vaccines have become a promising platform for cancer immunotherapy. During vaccination, naked or vehicle loaded mRNA vaccines efficiently express tumor antigens in antigen-presenting cells (APCs), facilitate APC activation and innate/adaptive immune stimulation. mRNA cancer vaccine precedes other conventional vaccine platforms due to high potency, safe administration, rapid development potent... ### The clinical progress of mRNA vaccines and immunotherapies - **Authors:** Ann Barbier, Allen Yujie Jiang, Peng Zhang, Richard Wooster, Daniel G. Anderson - **Journal:** Nature Biotechnology - **Published:** 2022-05-09 - **DOI:** [10.1038/s41587-022-01294-2](https://doi.org/10.1038/s41587-022-01294-2) - **Citations:** 824 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://www.nature.com/articles/s41587-022-01294-2.pdf) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W4229452462/llms.txt) ### Opportunities and Challenges in the Delivery of mRNA-Based Vaccines - **Authors:** Abishek Wadhwa, Anas Aljabbari, Abhijeet Lokras, Camilla Foged, Aneesh Thakur - **Journal:** Pharmaceutics - **Published:** 2020-01-28 - **DOI:** [10.3390/pharmaceutics12020102](https://doi.org/10.3390/pharmaceutics12020102) - **Citations:** 586 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://www.mdpi.com/1999-4923/12/2/102/pdf?version=1583032827) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3004416358/llms.txt) > In the past few years, there has been increasing focus on the use of messenger RNA (mRNA) as a new therapeutic modality. Current clinical efforts encompassing mRNA-based drugs are directed toward infectious disease vaccines, cancer immunotherapies, therapeutic protein replacement therapies, and treatment of genetic diseases. However, challenges that impede the successful translation of these molec... ### Clinical advances and ongoing trials of mRNA vaccines for cancer treatment - **Authors:** Cathrine Lund Lorentzen, John B.A.G. Haanen, Özcan Met, Inge Marie Svane - **Journal:** The Lancet Oncology - **Published:** 2022-09-26 - **DOI:** [10.1016/s1470-2045(22)00372-2](https://doi.org/10.1016/s1470-2045(22)00372-2) - **Citations:** 523 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](http://www.thelancet.com/article/S1470204522003722/pdf) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W4297102201/llms.txt) ### Self-assembled mRNA vaccines - **Authors:** Jeonghwan Kim, Yulia Eygeris, Mohit Gupta, Gaurav Sahay - **Journal:** Advanced Drug Delivery Reviews - **Published:** 2021-01-02 - **DOI:** [10.1016/j.addr.2020.12.014](https://doi.org/10.1016/j.addr.2020.12.014) - **Citations:** 509 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://www.ncbi.nlm.nih.gov/pmc/articles/7837307) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3119364115/llms.txt) ### Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort - **Authors:** Ulf Geisen, Dennis K Berner, Florian Tran, Melike SĂŒmbĂŒl, Lena Vullriede, Maria Ciripoi, Hayley M Reid, Annika Schaffarzyk, Ann Carolin Longardt, Jeanette Franzenburg, Paula Hoff, Jan Henrik Schirmer, Rainald Zeuner, Anette Friedrichs, Andrea Steinbach, Christine Knies, Robert Markewitz, Peter J. Morrison, Sascha Gerdes, Stefan Schreiber, Bimba F. Hoyer - **Journal:** Annals of the Rheumatic Diseases - **Published:** 2021-03-24 - **DOI:** [10.1136/annrheumdis-2021-220272](https://doi.org/10.1136/annrheumdis-2021-220272) - **Citations:** 375 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://ard.bmj.com/content/annrheumdis/80/10/1306.full.pdf) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3139490202/llms.txt) > INTRODUCTION: In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become a high priority. Persons at risk of severe disease, for example, those receiving immunosuppressive therapies for chronic inflammatory cdiseases (CIDs), are prioritised for vaccination. However, data concerning generation of protective antibody titres in immunosuppressed patients are scarce. Additionally, mRN... ### Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies - **Authors:** Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Shlomo Flechter, Rina Falb, Michael Gurevich - **Journal:** Therapeutic Advances in Neurological Disorders - **Published:** 2021-01-01 - **DOI:** [10.1177/17562864211012835](https://doi.org/10.1177/17562864211012835) - **Citations:** 363 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://doi.org/10.1177/17562864211012835) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3158831599/llms.txt) > BACKGROUND AND AIMS: The National Multiple Sclerosis Society and other expert organizations recommended that all patients with multiple sclerosis (MS) should be vaccinated against COVID-19. However, the effect of disease-modifying therapies (DMTs) on the efficacy to mount an appropriate immune response is unknown. We aimed to characterize humoral immunity in mRNA-COVID-19 MS vaccinees treated with... ### mRNA vaccine in cancer therapy: Current advance and future outlook - **Authors:** Youhuai Li, Mina Wang, Xueqiang Peng, Yingying Yang, Qishuang Chen, Jiaxing Liu, Qing‐Bai She, Jichao Tan, Chuyuan Lou, Zehuan Liao, Xuexin Li - **Journal:** Clinical and Translational Medicine - **Published:** 2023-08-01 - **DOI:** [10.1002/ctm2.1384](https://doi.org/10.1002/ctm2.1384) - **Citations:** 144 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ctm2.1384) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W4386116914/llms.txt) > Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wide variety of infectious diseases and cancer. In the past 2 years, SARS-CoV-2 mRNA vaccines have contributed tremendously against SARS-CoV2, which has prompted the arrival of the mRNA vaccine research boom, especially in the research of cancer vaccines. Compar... ### Advances in mRNA vaccine therapy for breast cancer research - **Authors:** Jiaying Li, Ruiyuan Jiang, Jia Wang, Xiaojia Wang - **Journal:** Discover Oncology - **Published:** 2025-05-06 - **DOI:** [10.1007/s12672-025-02542-y](https://doi.org/10.1007/s12672-025-02542-y) - **Citations:** 14 - **Source:** OpenAlex - **Access:** Open Access - **PDF:** [Download](https://link.springer.com/content/pdf/10.1007/s12672-025-02542-y.pdf) - **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W4410129890/llms.txt) > Breast cancer represents the most prevalent cancer among women globally, constituting approximately 30% of newly diagnosed female malignancies and serving as the second leading cause of cancer-related mortality, accounting for 11.6% of deaths. Despite notable advancements in survival rates and quality of life for breast cancer patients over recent decades-achieved through interventions such as sur... --- *Generated by [science-database.com](https://science-database.com) — The Knowledge Interface* *Full data available via [JSON API](https://science-database.com/api/v1/technology/mrna-therapies)*